UK Vaccination Schedule
| Age due | Vaccine given | Diseases covered | Usual site |
|---|---|---|---|
| 8 weeks old | DTaP/IPV/Hib/HepB (6-in-1) | Diphtheria, tetanus, pertussis, polio, H. influenzae type b, hepatitis B | Thigh |
| MenB | Meningococcal group B | Thigh | |
| Rotavirus | Rotavirus gastroenteritis | By mouth | |
| 12 weeks old | DTaP/IPV/Hib/HepB (6-in-1) | Diphtheria, tetanus, pertussis, polio, Hib, hepatitis B | Thigh |
| MenB | Meningococcal group B | Thigh | |
| Rotavirus | Rotavirus gastroenteritis | By mouth | |
| 16 weeks old | DTaP/IPV/Hib/HepB (6-in-1) | Diphtheria, tetanus, pertussis, polio, Hib, hepatitis B | Thigh |
| PCV13 | Pneumococcal (13 serotypes) | Thigh | |
| 12–13 months | PCV booster | Pneumococcal (13 serotypes) | Upper arm/thigh |
| MMRV (dose 1) | Measles, mumps, rubella, varicella (chickenpox) | Upper arm/thigh | |
| MenB booster | Meningococcal group B | Thigh | |
| Hib/MenC booster (children born on/before 30 Jun 2024 only) | Haemophilus influenzae type b; meningococcal C | Upper arm/thigh | |
| 18 months (children born on/after 1 Jul 2024) | DTaP/IPV/Hib/HepB (6-in-1) booster | Diphtheria, tetanus, pertussis, polio, Hib, hepatitis B | Upper arm/thigh |
| MMRV (dose 2) | Measles, mumps, rubella, varicella (chickenpox) | Upper arm/thigh | |
| 3 years 4 months | dTaP/IPV (pre-school booster) | Diphtheria, tetanus, pertussis, polio | Upper arm |
| MMRV (dose 2) (if not given at 18 months; children born on/before 30 Jun 2024) | Measles, mumps, rubella, varicella (chickenpox) | Upper arm | |
| Each autumn (age 2 to end of Year 11) | Influenza (LAIV; inactivated if LAIV unsuitable) | Influenza (also for clinical risk groups & pregnancy; UK nation policies vary) | Both nostrils (LAIV) / Upper arm |
| 12–13 years | HPV (usually 1 dose if under 25 and immunocompetent) | HPV-related cancers; genital warts | Upper arm |
| Around 14 years (Year 9) | Td/IPV (3-in-1 teenage booster) | Tetanus, diphtheria, polio | Upper arm |
| MenACWY | Meningococcal groups A, C, W, Y | Upper arm | |
| 17–18 years, and under-25s starting higher or residential further education‡ (time-limited offer, from 20 Jul 2026) | MenB (Bexsero, 2 doses ≥28 days apart)‡ | Meningococcal group B | Upper arm |
| 65 years old | PCV20 (Prevenar 20) (replaces PPV23) | Pneumococcal (20 serotypes) | Upper arm |
| From age 65 (each autumn) | Inactivated influenza vaccine | Seasonal influenza | Upper arm |
| Turning 65 (from 1 Sep each year)* | Shingles (Shingrix, 2 doses)* | Shingles (herpes zoster) | Upper arm |
| Ages 70–79 (and ≥18 if severely immunosuppressed)* | Shingles (Shingrix, 2 doses)* | Shingles (herpes zoster) | Upper arm |
| Ages 65–74 in certain clinical at-risk groups§ (from 1 Sep 2026) | RSV vaccine (Abrysvo, 1 dose)§ | Respiratory syncytial virus | Upper arm |
| 75 years and older (includes 80+ and all care home residents) | RSV vaccine (Abrysvo) | Respiratory syncytial virus | Upper arm |
* Shingles (Shingrix): The programme is being phased in by age. From 1 September 2023, people turning 65 each year become newly eligible, alongside anyone aged 70–79 not yet vaccinated. Once eligible, a person remains eligible until their 80th birthday. Severely immunosuppressed individuals aged 18+ are also eligible. The routine age of entry is being progressively lowered and is expected to reach age 60 by September 2028.
MMRV catch-up: From 1 November 2026 to 31 March 2028, a single MMRV catch-up dose is offered to children born between 1 January 2020 and 31 August 2022 who have not previously had chickenpox or 2 doses of varicella vaccine.
‡ Time-limited adolescent MenB offer: Following the MenB outbreak in Kent in March 2026, a one-off offer of 2 doses of Bexsero (at least 28 days apart) is available to those born 1 September 2007–31 August 2008, and to under-25s born on or after 21 July 2001 who are starting higher education or residential further education for the first time in 2026/27. First doses run from 20 July to 31 December 2026; second doses to 31 March 2027. In England the offer includes community pharmacy walk-in and booked appointments, and those using the education route are asked to bring confirmation of their place. Both doses are needed for protection. The JCVI recommended a future routine adolescent MenB programme at around 15 years of age on 16 July 2026; a government decision is awaited, so this is not yet part of the routine schedule.
§ RSV (ages 65–74 at-risk): From 1 September 2026 the older-adult RSV programme also covers adults aged 65–74 who have chronic respiratory disease, or immunosuppression due to disease or treatment (JCVI advice). A single dose of Abrysvo is given, and adults vaccinated in this cohort are not re-invited for a further dose at age 75. RSV vaccine can be offered at any time of year and may be co-administered with COVID-19 vaccine, but is not routinely scheduled alongside influenza vaccination.